Pectasides D, Economides N, Bourazanis J, Pozadzizou P, Gogou L, Koutsiouba P, Athanassiou A
First Department of Medical Oncology, Metaxas Cancer Hospital, Piraeus, Greece.
Am J Clin Oncol. 1994 Aug;17(4):307-12. doi: 10.1097/00000421-199408000-00005.
A total of 120 patients with squamous cell carcinoma of the cervix were prospectively monitored with simultaneous serum level estimations of SCC, CEA, and TATI in different stages and phases of their disease. Positive values were observed for SCC in 72 patients (60%), for CEA in 47 (39%), and for TATI in 12 (10%). There was no increase in the SCC serum levels in the early stages of disease (IA, IB, IIA), whereas they increased significantly with advancing stage. Serum marker levels quickly dropped to normal in patients with advanced stages (IIB or higher) or recurrent disease who responded to treatment, as well as in patients with early-stage disease following local therapy. In addition, 28 patients, who had a renewed progression after a complete remission with normal marker levels, showed an increase in SCC in 26 cases (92%) and CEA in 7 (25%). TATI did not vary in these patients. In patients whose disease did not respond to treatment, a change in serum marker levels cannot be evidenced with the available numbers. This study indicates that the routine measurement of all three markers is not justified in squamous cell carcinoma of the cervix, and that SCC estimation is a potential tool for monitoring the efficacy of treatment in advanced stages or relapse.
对120例宫颈鳞状细胞癌患者进行前瞻性监测，在疾病的不同阶段同时测定血清鳞状细胞癌抗原（SCC）、癌胚抗原（CEA）和组织多肽抗原（TATI）水平。72例患者（60%）的SCC呈阳性，47例（39%）的CEA呈阳性，12例（10%）的TATI呈阳性。在疾病早期阶段（IA、IB、IIA期），SCC血清水平没有升高，而随着病情进展其显著升高。对于晚期（IIB期或更高分期）或复发性疾病且对治疗有反应的患者，以及局部治疗后的早期疾病患者，血清标志物水平迅速降至正常。此外，28例在标志物水平正常且完全缓解后病情复发的患者中，26例（92%）的SCC升高，7例（25%）的CEA升高。这些患者的TATI没有变化。对于疾病对治疗无反应的患者，根据现有数据无法证明血清标志物水平有变化。本研究表明，在宫颈鳞状细胞癌中常规检测这三种标志物并不合理，并且SCC测定是监测晚期或复发疾病治疗效果的潜在工具。
